{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:16:20Z","timestamp":1760012180678,"version":"build-2065373602"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01115-0","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T11:33:05Z","timestamp":1760009585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors: a case series"],"prefix":"10.1038","volume":"9","author":[{"given":"Camila B.","family":"Xavier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"1115_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1115_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte, A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res. 38, 255 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1115_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","volume":"6","author":"YK Chae","year":"2018","unstructured":"Chae, Y. K. et al. Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J. Immunother. Cancer 6, 39 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"1115_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104135","volume":"192","author":"M Catalano","year":"2023","unstructured":"Catalano, M. et al. Immunotherapy-related biomarkers: confirmations and uncertainties. Crit. Rev. Oncol. Hematol. 192, 104135 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1115_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00355-7","volume":"10","author":"Y Pan","year":"2022","unstructured":"Pan, Y. et al. The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer. Biomark. Res. 10, 9 (2022).","journal-title":"Biomark. Res."},{"key":"1115_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1115_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/cncr.35063","volume":"130","author":"A Knisely","year":"2024","unstructured":"Knisely, A. et al. Phase 1\/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130, 400\u2013409 (2024).","journal-title":"Cancer"},{"key":"1115_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1200\/JCO.18.00145","volume":"37","author":"AM Tsimberidou","year":"2019","unstructured":"Tsimberidou, A. M. et al. Trial reporting in immuno-oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J. Clin. Oncol. 37, 72\u201380 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1115_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s11912-022-01264-6","volume":"24","author":"Y Jansen","year":"2022","unstructured":"Jansen, Y., van der Veldt, A. A. M., Awada, G. & Neyns, B. Anti-PD-1: when to stop treatment. Curr. Oncol. Rep. 24, 905\u2013915 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"1115_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","volume":"9","author":"L Sun","year":"2023","unstructured":"Sun, L. et al. Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer. JAMA Oncol. 9, 1075\u20131082 (2023).","journal-title":"JAMA Oncol."},{"key":"1115_CR11","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1200\/JCO.2019.37.15_suppl.3604","volume":"37","author":"M Nusrat","year":"2019","unstructured":"Nusrat, M. et al. Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts). J. Clin. Oncol. 37, 3604\u20133604 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1115_CR12","doi-asserted-by":"publisher","first-page":"S563","DOI":"10.1016\/j.annonc.2023.09.2019","volume":"34","author":"Z Sun","year":"2023","unstructured":"Sun, Z., Zhang, Q., Duan, Q., Tan, Y. & Chen, D. 873P Identification of PIK3CA mutation as a novel predictor of efficacious immunotherapy in head and neck cancer. Ann. Oncol. 34, S563\u2013S564 (2023).","journal-title":"Ann. Oncol."},{"key":"1115_CR13","doi-asserted-by":"publisher","unstructured":"Collins, N. B. et al. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003402 (2022).","DOI":"10.1136\/jitc-2021-003402"},{"key":"1115_CR14","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41416-020-0834-6","volume":"122","author":"T Vidotto","year":"2020","unstructured":"Vidotto, T. et al. Emerging role of PTEN loss in evasion of the immune response to tumours. Br. J. Cancer 122, 1732\u20131743 (2020).","journal-title":"Br. J. Cancer"},{"key":"1115_CR15","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1158\/1078-0432.CCR-23-1212","volume":"30","author":"GP Linette","year":"2024","unstructured":"Linette, G. P., Bear, A. S. & Carreno, B. M. Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations. Clin. Cancer Res. 30, 2017\u20132024 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1115_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01063-x","volume":"21","author":"A Watterson","year":"2023","unstructured":"Watterson, A. & Coelho, M. A. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. Cell Commun. Signal 21, 45 (2023).","journal-title":"Cell Commun. Signal"},{"key":"1115_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116058","volume":"171","author":"M Xu","year":"2024","unstructured":"Xu, M., Zhao, X., Wen, T. & Qu, X. Unveiling the role of KRAS in tumor immune microenvironment. Biomed. Pharmacother. 171, 116058 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"1115_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1070761","volume":"12","author":"L Peng","year":"2022","unstructured":"Peng, L. et al. Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: a real-world study in a Chinese population. Front Oncol. 12, 1070761 (2022).","journal-title":"Front Oncol."},{"key":"1115_CR19","doi-asserted-by":"publisher","unstructured":"Chmielewska, I. et al. Breaking the \u2018Undruggable\u2019 Barrier: anti-PD-1\/PD-L1 immunotherapy for non-small cell lung cancer patients with KRAS mutations\u2014a comprehensive review and description of single site experience. Cancers https:\/\/doi.org\/10.3390\/cancers15143732 (2023).","DOI":"10.3390\/cancers15143732"},{"key":"1115_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97566-z","volume":"11","author":"A Lauko","year":"2021","unstructured":"Lauko, A. et al. Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. Sci. Rep. 11, 18174 (2021).","journal-title":"Sci. Rep."},{"key":"1115_CR21","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/cac2.12327","volume":"42","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer. Cancer Commun. 42, 828\u2013847 (2022).","journal-title":"Cancer Commun."},{"key":"1115_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216595","volume":"588","author":"P Xu","year":"2024","unstructured":"Xu, P. et al. CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment. Cancer Lett. 588, 216595 (2024).","journal-title":"Cancer Lett."},{"key":"1115_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49316-6","volume":"13","author":"Q Wu","year":"2023","unstructured":"Wu, Q., Fang, C., Wang, X., Huang, S. & Weng, G. CHEK2 is a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma. Sci. Rep. 13, 21928 (2023).","journal-title":"Sci. Rep."},{"key":"1115_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-022-02469-0","volume":"41","author":"C Shi","year":"2022","unstructured":"Shi, C. et al. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. J. Exp. Clin. Cancer Res. 41, 268 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1115_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113437","volume":"196","author":"M Fakih","year":"2024","unstructured":"Fakih, M. et al. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases. Eur. J. Cancer 196, 113437 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1115_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1091669","volume":"13","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Case report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors. Front. Oncol. 13, 1091669 (2023).","journal-title":"Front. Oncol."},{"key":"1115_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1030147","volume":"13","author":"JW Conway","year":"2022","unstructured":"Conway, J. W. et al. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Front Immunol. 13, 1030147 (2022).","journal-title":"Front Immunol."},{"key":"1115_CR28","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1158\/1538-7445.AM2023-4406","volume":"83","author":"M Fakih","year":"2023","unstructured":"Fakih, M., Sandhu, J., Li, X. & Wang, C. Abstract 4406: Impact of site of metastases on response to immunotherapy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Cancer Res. 83, 4406\u20134406 (2023).","journal-title":"Cancer Res."},{"key":"1115_CR29","doi-asserted-by":"publisher","first-page":"e2118416","DOI":"10.1001\/jamanetworkopen.2021.18416","volume":"4","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases. JAMA Netw. Open 4, e2118416 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1115_CR30","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","volume":"30","author":"AJ Bullock","year":"2024","unstructured":"Bullock, A. J. et al. Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat. Med. 30, 2558\u20132567 (2024).","journal-title":"Nat. Med."},{"key":"1115_CR31","doi-asserted-by":"publisher","unstructured":"Tsimberidou, A. M. et al. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20240152 (2024).","DOI":"10.1084\/jem.20240152"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01115-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T11:33:05Z","timestamp":1760009585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01115-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1115"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01115-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Apostolia M. Tsimberidou declares receipt of Clinical Trial Research Funding (received through the institution): Immatics (Inst), OBI Pharma (Inst), Tempus (Inst), Parker Institute for Cancer Immunotherapy (Inst), Agenus (Inst), Novocure (Inst), Tvardi Therapeutics (Inst), Orionis (Inst), Tachyon (Inst), Vividion Therapeutics (Inst), AbbVie (Inst), Macrogenics (Inst), Anaveon (Inst); and has consulting\/advisory roles for Nex-I, BrYet, OBI Pharma. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"322"}}